Cherry Hill, New Jersey Clinical Trials

A listing of Cherry Hill, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 108 clinical trials
test cancer 54321

See protocol section 2 See <i>protocol</i> section 2 See <b>protocol</b> section 2. <p>this is p tag.</p> <h1>header</h1>

Hospital of the University of Pennsylvania
 (9.6 away) Contact site
  • 0 views
  • 20 Feb, 2026
  • 1 location
test cancer API Toggle On

See protocol section 2 See protocol section 2 See protocol section 2. this is p tag. header

Hospital of the University of Pennsylvania
 (9.6 away) Contact site
  • 0 views
  • 20 Feb, 2026
  • 1 location
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

bilateral orchidectomy
glomerular filtration rate
castration-resistant prostate cancer
dexamethasone
growth factor
Research Site
 (7.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +3 other locations
Niraparib/TTFields in GBM

Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).

karnofsky performance status
renal function
glioblastoma
recurrent glioblastoma
niraparib
Hospital of the University of Pennsylvania
 (9.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication

Prospective, multi-center, non-randomized study with consecutive, eligible subject enrollment at each site, for the evaluation of the ChEVAS System for Endovascular Repair of Complex Abdominal Aortic Aneurysms.

Cooper University Hospital
 (5.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +2 other locations
A Study of SY 5609 a Selective CDK7 Inhibitor in Advanced Solid Tumors

This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.

her2-negative breast cancer
endocrine therapy
measurable disease
alopecia
hair thinning
Sidney Kimmel Cancer Center
 (7.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +4 other locations
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Endocrine therapy is the initial treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancers. This study will evaluate the use of venetoclax in combination with capecitabine in adult participants with HR+, HER2-, metastatic breast cancer (MBC) who had disease progression following treatment …

endocrine therapy
growth factor
measurable disease
breast cancer
epidermal growth factor receptor
University of Pennsylvania /ID# 216357
 (9.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +15 other locations
Phase 2 Trial of CD19 Redirected Autologous T Cells

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients with central nervous system (CNS) relapse who did not receive …

Children's Hospital of Philadelphia
 (9.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

cns involvement
measurable disease
pleural effusions
metastatic disease
refractory ependymoma
Children's Hospital of Philadelphia
 (9.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +82 other locations
Evaluation of GLR2007 for Advanced Solid Tumors

This study is designed to determine the safety, tolerability, and optimal dosing of GLR2007 in participants with advanced solid tumors that do not respond well to standard clinical therapies.

measurable disease
erbb1
epidermal growth factor receptor
NTRK
BRAF
USA01
 (9.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +3 other locations